158 related articles for article (PubMed ID: 35212922)
21. The Treatment of Melanoma Brain Metastases.
Kibbi N; Kluger H
Curr Oncol Rep; 2016 Dec; 18(12):73. PubMed ID: 27822695
[TBL] [Abstract][Full Text] [Related]
22. Management of brain metastases in patients with melanoma.
Tarhini AA; Agarwala SS
Curr Opin Oncol; 2004 Mar; 16(2):161-6. PubMed ID: 15075910
[TBL] [Abstract][Full Text] [Related]
23. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
24. MRI characteristics in treatment for cerebral melanoma metastasis using stereotactic radiosurgery and concomitant checkpoint inhibitors or targeted therapeutics.
Rauch M; Tausch D; Stera S; Blanck O; Wolff R; Meissner M; Urban H; Hattingen E
J Neurooncol; 2021 May; 153(1):79-87. PubMed ID: 33761055
[TBL] [Abstract][Full Text] [Related]
25. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.
Glitza Oliva I; Tawbi H; Davies MA
Cancer J; 2017; 23(1):68-74. PubMed ID: 28114258
[TBL] [Abstract][Full Text] [Related]
26. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).
Lesueur P; Lequesne J; Barraux V; Kao W; Geffrelot J; Grellard JM; Habrand JL; Emery E; Marie B; Thariat J; Stefan D
Radiat Oncol; 2018 Jul; 13(1):138. PubMed ID: 30055640
[TBL] [Abstract][Full Text] [Related]
27. A comparison of survival rates for treatment of melanoma metastatic to the brain.
Stone A; Cooper J; Koenig KL; Golfinos JG; Oratz R
Cancer Invest; 2004; 22(4):492-7. PubMed ID: 15565805
[TBL] [Abstract][Full Text] [Related]
28. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis.
Zubatkina I; Ivanov P
J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Aizer AA; Rahman R; Guenette JP; Huang RY
Eur Radiol; 2021 Jun; 31(6):4114-4129. PubMed ID: 33241519
[TBL] [Abstract][Full Text] [Related]
30. Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma.
Hauswald H; Stenke A; Debus J; Combs SE
BMC Cancer; 2015 Jul; 15():537. PubMed ID: 26201853
[TBL] [Abstract][Full Text] [Related]
31. Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases.
ElJalby M; Pannullo SC; Schwartz TH; Parashar B; Wernicke AG
World Neurosurg; 2019 Jul; 127():397-404. PubMed ID: 31004856
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy for brain metastases.
Venur VA; Karivedu V; Ahluwalia MS
Handb Clin Neurol; 2018; 149():137-153. PubMed ID: 29307351
[TBL] [Abstract][Full Text] [Related]
33. Metastases to the central nervous system: Molecular basis and clinical considerations.
Wanleenuwat P; Iwanowski P
J Neurol Sci; 2020 May; 412():116755. PubMed ID: 32120132
[TBL] [Abstract][Full Text] [Related]
34. Molecular subtyping of brain metastases and implications for therapy.
Renfrow JJ; Lesser GJ
Curr Treat Options Oncol; 2013 Dec; 14(4):514-27. PubMed ID: 23907440
[TBL] [Abstract][Full Text] [Related]
35. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapies for melanoma brain metastases: which drug for whom and when?
Ramanujam S; Schadendorf D; Long GV
Chin Clin Oncol; 2015 Jun; 4(2):25. PubMed ID: 26112811
[TBL] [Abstract][Full Text] [Related]
37. Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases.
Abdulhaleem M; Johnston H; D'Agostino R; Lanier C; LeCompte M; Cramer CK; Ruiz J; Lycan T; Lo HW; Watabe K; O'Neill S; Whitlow C; White JJ; Tatter SB; Laxton AW; Su J; Chan MD
J Neurooncol; 2022 Mar; 157(1):101-107. PubMed ID: 35166988
[TBL] [Abstract][Full Text] [Related]
38. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
39. Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.
Sadetsky N; Hernandez A; Wallick CJ; McKenna EF; Surinach A; Colburn DE
Cancer Med; 2020 Sep; 9(17):6216-6224. PubMed ID: 32667719
[TBL] [Abstract][Full Text] [Related]
40. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy.
Weingarten N; Kruser TJ; Bloch O
Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
